Product news from 11/18/05 News Brief

The FDA approved Roche and Genentech's Tarceva (erlotinib) for a new indication as a treatment for patients with advanced pancreatic cancer. Tarceva has previously been approved by the FDA as a treatment for lung cancer.

Reliant Pharmaceuticals announced the FDA has approved its Supplemental New Drug Application for a new dosing regimen and label change for the fenofibrate therapy Antara (fenofibrate capsules) 43 mg and 130 mg. The new regimen enables patients to take Antara 130 mg capsules with or without food, increasing convenience for the 15% of adults in the U.S. with elevated triglycerides.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.